Live Breaking News & Updates on ஜெஃப் காஸ்டெல்லி

Stay updated with breaking news from ஜெஃப் காஸ்டெல்லி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript

Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

University Of Pennsylvania , United States , Eliana Rachel Merle , Mitchell Goldman , Subhalaksmi Baral Cowen , Bradleyl Campbell , Bradley Campbell , Asia Pacific , Jeffreyp Castelli , Johnf Crowley , Daphne Quimi , Andrew Faughnan , Kristen Kluska , Tachi Yamada , Jim Wilson , Jeff Castelli , Ellie Merle , Daphnee Quimi , John Crowley , Development Officer , Global Research , Amicus Therapeutics , Investment Bank Analyst , European Commission , Disease Center , Exchange Commission ,

Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript

Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

University Of Pennsylvania , United States , United Kingdom , Eliana Rachel Merle , Mitchell Goldman , Subhalaksmi Baral Cowen , Anupam Rama , Bradleyl Campbell , Yun Zhong , Bradley Campbell , Asia Pacific , Jeffreyp Castelli , Johnf Crowley , Salveen Richter , Gil Blum , Daphne Quimi , Andrew Faughnan , Kristen Kluska , Tachi Yamada , Jim Wilson , Jeff Castelli , Ellie Merle , Daphnee Quimi , John Crowley , Joseph Schwartz , Development Officer ,

Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript

Operator
Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics First Quarter 2021 Financial Results Conference Call and Webcast. [Operator Instructions]
I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Head of Investor Relations. You may begin.
Andrew Faughnan
Thank you, Mary.
Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics first quarter 2021 financial results and corporate highlights.
Speaking on today s call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A, we ll have Dr. Mitchell Goldman, Senior Vice President of Clinical Research joining. ....

United States , University Of Pennsylvania , Mitchell Goldman , Fisher Brammer , Anupam Rama , Salveen Richter Goldman Sachs , Debjit Chattopadhyay , Mohit Bansal Citigroup , Bradley Campbell , Salveen Richter , Daphne Quimi , Andrew Faughnan , Kristen Kluska , Kristen Kluska Cantor Fitzgerald , Jim Wilson , Sanofi Genzyme , Jeff Castelli , Sebastien Martel , John Crowley , Tessa Romero Jpmorgan , Tazeen Ahmad , Mohit Bansal , Joseph Schwartz , Development Officer , Goldman Sachs , Amicus Therapeutics Inc ,

Amicus Therapeutics Announces Successful Pre-BLA Meeting

Submissions to Seek Approval in both ERT Naïve and ERT Switch Pompe Patients
Completion of Rolling Biologics License Application On-Track by end of 2Q21
PHILADELPHIA, May 03, 2021 (GLOBE NEWSWIRE) Amicus Therapeutics (NASDAQ:FOLD) today announced the completion of a successful Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) for AT-GAA (cipaglucosidase alfa co-administered with miglustat), its investigational two-component therapy for the treatment of Pompe disease. Based on this formal pre-BLA meeting and the final written communication received from the FDA, Amicus intends to complete the rolling BLA submission for cipaglucosidase alfa and submit a New Drug Application for miglustat. ....

United States , Andrew Faughnan , Diana Moore , Johnf Crowley , Jeff Castelli , Amicus Therapeutics , European Medicines Agency , Drug Administration , Head Of Global Corporate Communications , Existing Data Support Regulatory , Seek Approval , Pompe Patients , Rolling Biologics License Application On Track , Typeb Pre Biologics License Application , New Drug Application , Chief Executive Officer , Chief Development Officer , Breakthrough Therapy Designation , Authorization Applications , Private Securities Litigation Reform Act , Pompe Disease , Annual Report , Global Corporate , ஒன்றுபட்டது மாநிலங்களில் , டயானா மூர் , ஜெஃப் காஸ்டெல்லி ,

Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript

Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Amicus Therapeutics Inc (NASDAQ: FOLD)
Popular Searches
Operator
Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Fourth Quarter 2020 Fiscal Year Results Conference Call and Webcast. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Head of Investor Relations. You may begin.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company s SEC filings. Please ....

United States , University Of Pennsylvania , Mitchell Goldman , Anupam Rama , Bradleyl Campbell , Henri Termeer , Debjit Chattopadhyay , Mohit Bansal Citigroup , Bradley Campbell , Elizabeth Webster Goldman Sachs , Jeffreyp Castelli , Johnf Crowley , Salveen Richter , Daphne Quimi , Andrew Faughnan , Kristen Kluska , Kristen Kluska Cantor Fitzgerald , Jim Wilson , Aaron Welch Guggenheim , Jeff Castelli , Rossella Passero , Fabry Pompe , Anvita Cowen , John Crowley , Tazeen Ahmad , Mohit Bansal ,